Bellicum Pharma (BLCM) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Bellicum Pharma (BLCM) Misses Q2 EPS by 4c

Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update

August 8, 2016 4:05 PM EDT

Two INDs cleared by FDA to begin studies of controlled CAR T and TCR product candidates

Conference call and webcast to be held Monday, August 8, 2016 at 5 p.m. Eastern

HOUSTON--(BUSINESS WIRE)-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the second quarter of 2016 and provided an update on recent developments.

In the last six months, we have achieved important milestones... More